Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) EBT (2021 - 2025)

Historic EBT for Coeptis Therapeutics Holdings (COEPW) over the last 5 years, with Q3 2025 value amounting to -$2.9 million.

  • Coeptis Therapeutics Holdings' EBT fell 5849.64% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.7 million, marking a year-over-year decrease of 1759.55%. This contributed to the annual value of -$10.9 million for FY2024, which is 4885.2% up from last year.
  • Latest data reveals that Coeptis Therapeutics Holdings reported EBT of -$2.9 million as of Q3 2025, which was down 5849.64% from -$4.3 million recorded in Q2 2025.
  • In the past 5 years, Coeptis Therapeutics Holdings' EBT registered a high of -$139650.0 during Q1 2021, and its lowest value of -$19.2 million during Q1 2022.
  • For the 5-year period, Coeptis Therapeutics Holdings' EBT averaged around -$5.0 million, with its median value being -$3.3 million (2023).
  • Per our database at Business Quant, Coeptis Therapeutics Holdings' EBT crashed by 1363411.6% in 2022 and then surged by 7120.04% in 2024.
  • Quarter analysis of 5 years shows Coeptis Therapeutics Holdings' EBT stood at -$139650.0 in 2021, then tumbled by 2007.4% to -$2.9 million in 2022, then fell by 27.61% to -$3.8 million in 2023, then increased by 19.81% to -$3.0 million in 2024, then increased by 3.75% to -$2.9 million in 2025.
  • Its EBT stands at -$2.9 million for Q3 2025, versus -$4.3 million for Q2 2025 and -$3.4 million for Q1 2025.